I think because NP is not going to take this analysis lying down. If they are close enough that 293 patients could hit the golden endpoint, NP might be asking "why wait an extra couple weeks, just to prove what we already know?"

Exhibit A from the PR
"Concurrently, we are seeking ongoing guidance from the U.S. Food and Drug Administration and regulatory agencies in other countries for a swift regulatory approval pathway for leronlimab to treat COVID-19"

I'm thinking they are letting everyone know that another interim analysis was recommended at a lower patient count....Hey FDA wake up we're almost there, should we let more people die to hit your "special number" or can we stop this right now? I mean remdesivir was "trending", so are we.